first week weight loss semaglutide What to Expect During the After Your First What Should I Expect During

Cell Metab 3:153165 Hadjiyanni I, Siminovitch KA, Danska JS, Drucker DJ (2010) Glucagon-like peptide-1 receptor signalling selectively regulates murine lymphocyte proliferation and maintenance of peripheral regulatory T cells

Final Verdict: 7 Clinical Facts Ozempic is not licensed for weight loss in the UK Wegovy is the licensed semaglutide weight management product Mounjaro and Wegovy are different drugs tirzepatide (dual GLP-1/GIP) vs semaglutide (GLP-1 only) In the SURMOUNT-5 head-to-head trial, Mounjaro produced 20.2% vs Wegovys 13.7% average weight loss Wegovy is approximately 75/month cheaper at Slinic maintenance doses important for cost-sensitive patients Wegovy has the NICE cardiovascular indication (April 2026) Mounjaro does not yet have this label Wegovy now has a licensed oral version (MHRA June 2026) Mounjaro does not yet have an oral equivalent Neither Ozempic off-label nor compounded alternatives are appropriate when licensed products are readily available from a GPhC-registered UK pharmacy Slinic prescribes Mounjaro and Wegovy both correctly licensed, both from Eli Lilly and Novo Nordisk authorised supply chains, both reviewed by a registered UK prescriber

Currently, Ozempic remains solely FDA-approved for Type 2 Diabetes, while Wegovy is FDA-approved for chronic weight management

Ozempic has been FDA-approved to help manage type 2 diabetes, while Wegovy is approved to manage weight

symptoms such as palpitations, pallor, or abdominal pain require urgent assessment

Yes, GLP-1 medications can generally be used in patients with high blood pressure, though careful provider oversight is essential